Recently, we collected multiple clear cell sarcoma cell lines and we are in the process of sequencing these cells so that we can learn more about their secondary mutations. The most common primary mutation for clear cell sarcoma is referred to as a chromosomal translocation – basically a gene that should be on one chromosome has swapped places with a gene on a different chromosome. Cancer is tricky though and usually drugs that target only one mutation don’t work long term since secondary mutations usually lead to other challenges, like resistance to drugs. We have identified and gathered several (over 60) promising drugs and we are in the process of starting drug studies on all of the cell lines so we can see what works and how well it works. This information will be used, along with sequencing information, to generate a computer model that helps us decide which combination of drugs would work the best for the disease. I am really looking forward to having more information about the secondary mutations present in clear cell sarcoma and seeing what therapeutic targets will be revealed from the modeling program. Most importantly though, I am looking forward to helping patients who lack a standard of care beyond surgery.
Our Nanocourse this summer (https://cc-tdi.kindful.com/register/pediatric-cancer-nanocourse-2019) is featuring many researchers who specialize in clear cell sarcoma and this course is bringing many families together. We are very thankful to the Sara’s Cure Foundation for their generosity and support and for helping us to make pediatric cancer universally survivable!
